1. The risk factors of colistin methanesulfonate associated nephrotoxicity
- Author
-
Melek Gura, E. Nursen Koltka, Elif Tukenmez Tigen, Arzu Dogru, Haluk Vahabaoglu, Tigen, Elif Tukenmez, Koltka, E. Nursen, Dogru, Arzu, Gura, Melek, and Vahabaoglu, Haluk
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Short Communication ,030106 microbiology ,Apache II score ,Critical Care and Intensive Care Medicine ,Nephrotoxicity ,03 medical and health sciences ,health services administration ,Internal medicine ,Intensive care ,medicine ,risk factors ,COHORT ,Significant risk ,Risk factor ,Intensive care medicine ,health care economics and organizations ,business.industry ,nephrotoxicity ,medicine.disease ,SODIUM ,Health evaluation ,Colistin ,business ,Colistin methanesulfonate ,Kidney disease ,medicine.drug - Abstract
Purpose: The risk factors of colistin methanesulfonate (CMS) associated nephrotoxicity are important. Our study attempts look into the prevalence of CMS-associated nephrotoxicity in Intensive Care Units (ICUs), and related risk factors. Materials and Methods: The study was conducted between September 2010 and April 2012 on 55 patients who underwent CMS treatment. Nephrotoxicity risk was defined based on the Risk Injury Failure Loss End-stage kidney disease criteria. Results: Fifty-five patients included in the study. A total of 22 (40%) patients developed nephrotoxicity. The correlation was detected between nephrotoxicity and patients over 65 with a high Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score. APACHE II score was revealed an independent risk factor for nephrotoxicity. Conclusion: Advanced age and a high APACHE II score are significant risk factors in the development of nephrotoxicity at ICUs following CMS use. Patient selection and close monitoring are critical when starting CMS treatment.
- Published
- 2016
- Full Text
- View/download PDF